Stockscreener 앱 받기
3.115
2.13%
0.065
Savara Inc 주식(SVRA)의 최신 뉴스
Savara publishes IMPALA-2 clinical trial results in NEJM - TipRanks
Savara’s autoimmune PAP treatment shows positive phase 3 results - Investing.com
9.8% Lung Function Improvement: Savara's Breakthrough PAP Treatment Succeeds in Largest-Ever Phase 3 Trial - Stock Titan
New England Journal of Medicine (NEJM) to Publish Results From Savara’s Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Ariva
Savara to Resubmit BLA for Rare Lung Disease Treatment as Losses Widen in Q2 - MSN
Can Savara Inc. Escape Recent Bear Channel2025 Institutional Moves & AI Enhanced Trading Alerts - thegnnews.com
Savara Inc. shares fall 2.62% after-hours following the announcement of new data presentations at ERS Congress 2025. - AInvest
Savara partner to present data on dried blood spot test for aPAP diagnosis By Investing.com - Investing.com South Africa
Savara partner to present data on dried blood spot test for aPAP diagnosis - Investing.com
Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025 - DutchNews.nl
Major Phase 3 Data Coming: Savara's Breakthrough Treatment for Ultra-Rare Lung Disease aPAP at ERS 2025 - Stock Titan
Savara upgraded to Buy by H.C. Wainwright on potential Molbreevi marketing application resubmission. - AInvest
Oppenheimer Assumes Coverage of Savara (SVRA) With an Outperform Rating - MSN
Savara Inc. Reports Increased Loss Amid Ongoing R&D Investments - MSN
What analysts say about Savara Inc. stockJuly 2025 Sentiment & Daily Oversold Stock Bounce Ideas - thegnnews.com
Savara Inc. (NASDAQ: SVRA): A Re-Rating Catalyst Unfolds as Clinical Progress and Analyst Upgrades Signal Long-Term Value - AInvest
Published on: 2025-08-16 20:17:05 - metal.it
Trendline Breach Raises Concern for Savara Inc. Investors2025 Trading Recap & Advanced Swing Trade Entry Alerts - metal.it
Savara Receives Analyst Upgrade and Price Target Increase - AInvest
Savara Upgraded to Buy by H.C. Wainwright Amid Resubmission Prospects - AInvest
H.C. Wainwright upgrades Savara to Buy on resubmission prospects - MSN
What makes Savara Inc. stock price move sharplyMarket Growth Report & Capital Efficient Trading Techniques - 선데이타임즈
Will Savara Inc. Recover After Recent DeclineTake Profit & Trade Opportunity Analysis Reports - 선데이타임즈
Savara stock upgraded at H.C. Wainwright (SVRA:NASDAQ) - Seeking Alpha
Savara Shares Rise After Upgrade From HC Wainwright - MarketScreener
Savara stock rating upgraded to Buy by H.C. Wainwright on BLA resubmission plans - Investing.com Australia
HC Wainwright Upgrades Savara to Buy From Neutral, $5 Price Target - MarketScreener
Oppenheimer raises Savara stock price target to $6 on BLA resubmission plans - Investing.com
Savara price target raised to $6 from $5 at Oppenheimer - TipRanks
Oppenheimer Adjusts Price Target on Savara to $6 From $5, Maintains Outperform Rating - MarketScreener
Is There Enough Volume to Lift Savara Inc.2025 Big Picture & Weekly Market Pulse Alerts - newsyoung.net
Savara Posts Loss for Q2 2025 as Earnings Beat Fails to Drive Market Optimism - AInvest
HC Wainwright & Co. Upgrades Savara (SVRA) - MSN
Savara reports Q2 EPS (14c), consensus (12c) - MSN
Savara Inc.’s Price Action Aligns with Quant SignalsJuly 2025 Spike Watch & Free Community Supported Trade Ideas - sundaytimes.kr
Why Savara (SVRA.O) Spiked 14% Despite No Fresh News: A Technical and Market Flow Deep Dive - AInvest
Savara (SVRA.O) Surges 8.15% on Intraday Momentum – But No Technical or Order-Flow Confirmation - AInvest
More layoffs at Evotec; Savara to work with Fujifilm as manufacturing partner - Endpoints News
Savara Expects FDA Approval for Fujifilm-Manufactured Drug Substance in December - AInvest
Savara Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Savara Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update - Bluefield Daily Telegraph
What machine learning models say about Savara Inc.Reversal Signal Prediction Based on Volume - Newser
Can a trend reversal in Savara Inc. lead to recoveryFree AI Based High Gain Watchlist Scanner - Newser
How Savara Inc. stock performs during market volatilityReal-Time Equity Price Action Analysis - Newser
Is Savara Inc. forming bullish engulfing patternsHigh Momentum Profit Stocks - thegnnews.com
Savara Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Why Savara Inc. stock attracts strong analyst attentionFree Conservative Long Term Growth Plans - Newser
Savara Showcases Promising Phase 3 Trial Data for Molgramostim at ATS 2025 - MSN
Is Savara Inc. stock overvalued or undervaluedSuperior capital gains - Jammu Links News
What are Savara Inc. company’s key revenue driversOverwhelming financial success - Jammu Links News
What markets is WTBA expanding into Is Savara Inc. stock a good long term investment option - Jammu Links News
When is Savara Inc. stock expected to show significant growthFree Stock Selection - Jammu Links News
How does Savara Inc. generate profit in a changing economyCapitalize on emerging investment opportunities - Jammu Links News
Does Savara Inc. stock perform well during market downturnsFree Risk Assessment Services - Jammu Links News
Why is Savara Inc. stock attracting strong analyst attentionRapid growth trajectories - Jammu Links News
What are analysts’ price targets for Savara Inc. in the next 12 monthsFree AI-Backed Trading Signals - Jammu Links News
How many analysts rate Savara Inc. as a “Buy”Consistent triple-digit returns - Jammu Links News
0.72%
0.49%
자본화:
|
볼륨(24시간):